TYMS and acute lymphoblastic leukemia: We believe that our finding, increased gastrointestinal toxicity in ALL patient carriers of TYMS 6bp deletion, is a result of the interaction of MTX and TYMS, whose low expression level enables more effective action of MTX, leading both to a better therapeutic effect and more prominent toxicity.